BioXcel Therapeutics
Price & Volume
Stats
See more52W Range | $0.73-$8.08 |
Market Cap | $25.2M |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $680,000 |
Revenue Growth (YoY) | 22.6% |
Gross Profit (12 Mos) | $247,000 |
Diluted EPS | -$4.77 |
News
See moreYahoo Finance • 3 months ago
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Yahoo Finance • 3 months ago
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Yahoo Finance • 4 months ago
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
About
CEO | Dr. Vimal D. Mehta Ph.D. |
CFO | Mr. Richard I. Steinhart MBA |
Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 29 |